philip philip, md, shares his perspective on using tas-102 and regorafenib in crc patients
Published 7 years ago • 197 plays • Length 1:36
Download video MP4
Download video MP3
Similar videos
-
1:21
alan p. venook, md, provides his perspective on using tas-102 and regorafenib in crc patients
-
2:05
howard s. hochster, md, provides perspective on how to use tas-102 and regorafenib in crc patients
-
0:51
philip philip, md explains how to integrate regorafenib and trifluridine for 2nd line mcrc treatment
-
0:56
philip philip, md on stivarga (regorafenib) dosage in 2nd line treatment of mcrc
-
2:04
philip philip, md, shares opinion on treatment of a brca pancreatic cancer patient
-
1:16
dr. bekaii-saab on tas-102 and regorafenib in mcrc
-
3:00
philip philip, md, on the phase 2 study comparing chemo with or without veliparib in pancreas
-
1:16
dr. eng on roles of regorafenib and tas-102 in crc treatment
-
1:12
dr. lenz on choosing between regorafenib and tas-102 in crc
-
4:45
philip philip, md, on whether resected pancreatic cancer patients should be offered adjuvant therapy
-
0:53
philip philip, md on the importance of ipilimumab prior to nivolumab in mcrc patients
-
4:53
debate: salvage therapy for mcrc? - tas-102 followed by regorafenib
-
2:06
howard s. hochster, md, differentiates regorafenib from 5fu and tas-102
-
0:20
copy of dr. bekaii-saab on tas-102 and regorafenib in mcrc
-
2:13
later-line treatment for mcrc: regorafenib or tas-102?
-
9:06
debate: is there an optimal treatment for refractory colorectal cancer? - tas-102 or regorafenib
-
0:57
choosing between tas-102 and regorafenib in colorectal cancer
-
7:54
regorafenib vs tas-102 salvage therapy
-
1:04
marwan g. fakih, md, on combining regorafenib checkpoint inhibition in advanced crc
Clip.africa.com - Privacy-policy